Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis.

Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD.

Neuron. 1998 Mar;20(3):589-602.

2.
3.

Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis.

Rothstein JD.

Clin Neurosci. 1995-1996;3(6):348-59. Review.

PMID:
9021256
4.

Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis.

Iwasaki Y, Ikeda K, Kinoshita M.

Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):511-8. Review.

PMID:
12769603
5.

Serotonergic mechanisms in amyotrophic lateral sclerosis.

Sandyk R.

Int J Neurosci. 2006 Jul;116(7):775-826. Review.

PMID:
16861147
6.

[The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].

Van den Bosch L.

Verh K Acad Geneeskd Belg. 2006;68(4):249-69. Review. Dutch.

PMID:
17214440
7.

Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex.

Wilson JM, Shaw CA.

Neurochem Int. 2007 Jun;50(7-8):1067-77. Review.

PMID:
17095122
8.

The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype.

Robinson MB.

Neurochem Int. 1998 Dec;33(6):479-91. Review.

PMID:
10098717
9.
10.

The role of RNA processing in the pathogenesis of motor neuron degeneration.

Bäumer D, Ansorge O, Almeida M, Talbot K.

Expert Rev Mol Med. 2010 Jul 20;12:e21. doi: 10.1017/S1462399410001523. Review.

PMID:
20642879
11.

The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS).

Strong MJ.

J Neurol Sci. 2010 Jan 15;288(1-2):1-12. doi: 10.1016/j.jns.2009.09.029. Review.

PMID:
19840884
12.

Pathogenic mechanisms in sporadic amyotrophic lateral sclerosis.

Eisen A, Krieger C.

Can J Neurol Sci. 1993 Nov;20(4):286-96. Review.

PMID:
8313244
13.

Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.

Rothstein JD.

Adv Neurol. 1995;68:7-20; discussion 21-7. Review.

PMID:
8787245
14.
15.

Aberrant RNA processing events in neurological disorders.

Anthony K, Gallo JM.

Brain Res. 2010 Jun 18;1338:67-77. doi: 10.1016/j.brainres.2010.03.008. Review.

PMID:
20226177
16.

Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.

Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB.

J Cell Physiol. 2011 Oct;226(10):2484-93. doi: 10.1002/jcp.22609. Review.

17.

Excitotoxicity in ALS: Overstimulation, or overreaction?

King AE, Woodhouse A, Kirkcaldie MT, Vickers JC.

Exp Neurol. 2016 Jan;275 Pt 1:162-71. doi: 10.1016/j.expneurol.2015.09.019. Review.

PMID:
26584004
18.
19.

Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis.

Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, Fornai F, Siciliano G.

Arch Ital Biol. 2011 Mar;149(1):151-67. doi: 10.4449/aib.v149i1.1267. Review.

PMID:
21412722
20.

Genetics of amyotrophic lateral sclerosis: an update.

Chen S, Sayana P, Zhang X, Le W.

Mol Neurodegener. 2013 Aug 13;8:28. doi: 10.1186/1750-1326-8-28. Review.

Items per page

Supplemental Content

Support Center